Erbitux Approval For Colorectal Cancer Sought In Japan
This article was originally published in PharmAsia News
Executive Summary
Merck KGaA has requested a priority review in its regulatory submission for the biologic Erbitux (cetuximab) to the Japanese Pharmaceuticals and Medical Devices Agency, the firm told "The Pink Sheet" DAILY
You may also be interested in...
Vectibix Vs. Erbitux: The Race For A First-Line Colorectal Cancer Indication
Expansion into the first-line colorectal cancer setting offers a significant opportunity for Amgen and ImClone's respective EGFR inhibitors.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).